Jan Poolman
YOU?
Author Swipe
View article: Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022
Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022 Open
These observations demonstrate that IED is a substantial and growing global health concern that disproportionally affects older adults.
View article: A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models
A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models Open
Staphylococcus aureus is a major cause of bacterial infection-related deaths. Increasing antimicrobial resistance highlights the urgent need for effective preventative strategies. Antibody-mediated opsonophagocytosis, the key mechanism for…
View article: Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States
Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States Open
View article: Epidemiology of invasive <i>Escherichia coli</i> disease in adults in England, 2013–2017
Epidemiology of invasive <i>Escherichia coli</i> disease in adults in England, 2013–2017 Open
Extraintestinal pathogenic Escherichia coli (ExPEC) causes invasive E. coli disease (IED), including bacteraemia and (uro)sepsis, resulting in a high disease burden, especially among older adults. This study describes the epidemiology of I…
View article: A retrospective global study of the prevalence of O-serotypes of invasive <i>Escherichia coli</i> disease in patients admitted to tertiary care hospitals
A retrospective global study of the prevalence of O-serotypes of invasive <i>Escherichia coli</i> disease in patients admitted to tertiary care hospitals Open
Invasive Escherichia coli disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for E. coli survival. To inform EXPEC9V development, a…
View article: Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning
Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning Open
View article: A microbiological and genomic perspective of globally collected <i>Escherichia coli</i> from adults hospitalized with invasive <i>E. coli</i> disease
A microbiological and genomic perspective of globally collected <i>Escherichia coli</i> from adults hospitalized with invasive <i>E. coli</i> disease Open
Objectives Escherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations at increased risk. We aimed to est…
View article: A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI Open
View article: Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study Open
View article: Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study Open
Purpose Invasive Escherichia coli disease (IED) encompasses a diverse range of sterile site infections. This study evaluated the feasibility of capturing IED among community-dwelling older adults to inform the implementation of a phase 3 e…
View article: 2465. O-serotype Distribution of <i>Escherichia coli</i> Causing Invasive Disease in Tertiary Care Hospital Patients
2465. O-serotype Distribution of <i>Escherichia coli</i> Causing Invasive Disease in Tertiary Care Hospital Patients Open
Background Escherichia coli is a common Gram-negative bacterium that can infect normally sterile body sites and cause invasive E. coli disease (IED) including bacteremia, sepsis and septic shock. E. coli surface O-antigens are important vi…
View article: Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study Open
Background ExPEC10V is a bioconjugate vaccine containing O-antigen polysaccharides of 10 extraintestinal pathogenic Escherichia coli (ExPEC) serotypes. This phase 1/2a study (NCT03819049) assessed the safety, reactogenicity, and immunogeni…
View article: IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE
IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE Open
Intro: The safety, reactogenicity, and immunogenicity of VAC52416 (ExPEC10V), a vaccine candidate to prevent invasive Escherichia coli disease, was assessed in a phase 1/2a study (NCT03819049). Results from Cohort 1 have been presented. He…
View article: CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2)
CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2) Open
Intro: Published data is limited in describing clinical features and disease burden of invasive Escherichia coli disease (IED). This study characterized bacteremic and non-bacteremic IED in relation to clinical features and multidrug resis…
View article: Colonization with Escherichia coli ST131-H30R (H30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to H30R
Colonization with Escherichia coli ST131-H30R (H30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to H30R Open
An exceptional gut-colonizing ability may underlie the dramatic epidemiological success of the multidrug-resistant H30R subclone of Escherichia coli sequence type 131 (O25b:K+:H4). In order to inform the development of colonization-prevent…
View article: Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive<i>Escherichia Coli</i>Disease in Patients Admitted in Tertiary Care Hospitals
Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive<i>Escherichia Coli</i>Disease in Patients Admitted in Tertiary Care Hospitals Open
Background Invasive Escherichia coli disease (IED), including bloodstream infection, sepsis, and septic shock, can lead to high hospitalization and mortality rates. This multinational study describes the clinical profile of patients with I…
View article: 120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study Open
Background This Phase 1/2a study (NCT03819049) assessed the safety, reactogenicity, and immunogenicity of 3 doses of VAC52416 (ExPEC10V), a vaccine candidate to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. …
View article: 1823. Clinical Profile and Antimicrobial Susceptibility of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Hospitalized Adults Aged ≥60 Years
1823. Clinical Profile and Antimicrobial Susceptibility of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Hospitalized Adults Aged ≥60 Years Open
Background Invasive extraintestinal pathogenic Escherichia coli disease (IED) occurs more frequently with increasing age, and antimicrobial resistance (AMR) can complicate treatment. Yet IED is under-monitored by major disease surveillance…
View article: 235. Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting
235. Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting Open
Background A vaccine developed to prevent invasive extraintestinal pathogenic Escherichia coli disease (IED) is being evaluated in a phase 3 clinical trial (NCT04899336). However, historical performance of similar clinical trials has been …
View article: Genomics and pathotypes of the many faces of<i>Escherichia coli</i>
Genomics and pathotypes of the many faces of<i>Escherichia coli</i> Open
Escherichia coli is the most researched microbial organism in the world. Its varied impact on human health, consisting of commensalism, gastrointestinal disease, or extraintestinal pathologies, has generated a separation of the species int…
View article: Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic <i>Escherichia coli</i> Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies
Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic <i>Escherichia coli</i> Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies Open
Background Extraintestinal pathogenic Escherichia coli (ExPEC) is the leading cause of bacteremia worldwide, with older populations having increased risk of invasive bacterial disease. Increasing resistance to first-line antibiotics and em…
View article: Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines
Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines Open
The development and use of antibacterial glycoconjugate vaccines have significantly reduced the occurrence of potentially fatal childhood and adult diseases such as bacteremia, bacterial meningitis, and pneumonia. In these vaccines, the co…
View article: Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a <i>Staphylococcus aureus</i> Minipig Deep Surgical Wound Infection Model
Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a <i>Staphylococcus aureus</i> Minipig Deep Surgical Wound Infection Model Open
Vaccines against Staphylococcus aureus have eluded researchers for >3 decades while the burden of staphylococcal diseases has increased. Early vaccine attempts mainly used rodents to characterize preclinical efficacy, and all subsequent…
View article: O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands
O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands Open
A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.
View article: Reply by Authors
Reply by Authors Open
No AccessJournal of UrologyAdult Urology1 Mar 2021Reply by Authorsis a reply to letterEditorial Comment Steven Rosenberg, Marc Bonten, Wouter Haazen, Bart Spiessens, Darren Abbanat, Oscar Go, Florian Wagenlehner, Neal Shore, Yosuke Hagiwar…
View article: Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study Open
This study provides an estimate of microbiologically confirmed invasive ExPEC disease incidence following TRUS-PNB. Information on E. coli O-serotype distribution and associated antibiotic resistance profiles from invasive ExPEC dis…
View article: Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections
Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections Open
View article: 2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants
2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants Open
Background The ExPEC4V vaccine contains 4 Escherichia coli O-antigens (O1A, O2, O6A, O25B) conjugated to exotoxin protein A and is being studied for prevention of Invasive Extraintestinal pathogenic E. coli (ExPEC) Disease (IED). This phas…
View article: Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro
Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro Open
View article: Building teams to create innovative new vaccines
Building teams to create innovative new vaccines Open
My fascination with life and its natural enemies – pathogens – started in my youth. I grew up on a cattle farm, run by my uncle after my father passed away when I was only 2½ years old. Seeing my u...